2023
MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow C, Rae A, Taparra K, Kumar P, Siegelin M, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Horowitz D, Kachnic L, Neugut A, Yu J, Cheng S, Wang T. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research 2023, 29: 4399-4407. PMID: 37611077, PMCID: PMC10872921, DOI: 10.1158/1078-0432.ccr-23-1295.Peer-Reviewed Original ResearchConceptsAssociated with worse survivalOverall survivalMGMT promoter statusUnmethylated MGMTWorse survivalPrognostic of progression-free survivalPromoter statusMultivariate Cox proportional hazards regression modelsWorld Health Organization gradeProgression-free survivalNational Cancer DatabaseCox proportional hazards regression modelsMGMT promoter methylationProportional hazards regression modelsGuiding treatment decisionsHazards regression modelsCourse of treatmentPredictive of responseMultiagent chemotherapyMGMT promoterCancer DatabaseMMGMTAlkylating chemotherapyChemotherapyEligible patients
2021
Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis
Gao S, Yu J, Park H, Decker R. Optimal Timing of SBRT for Treatment of Oligometastatic Disease: A Single Institution Retrospective Analysis. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: e476-e477. DOI: 10.1016/j.ijrobp.2021.07.1324.Peer-Reviewed Original ResearchCurative-intent stereotactic body radiation therapyStereotactic body radiation therapyUpfront systemic therapyKarnofsky performance scoreProgression-free survivalSystemic therapyOverall survivalOligometastatic diseaseSequential therapyWorse survivalOligometastatic settingConcurrent therapyImproved survivalHigher Karnofsky performance scoreSingle-institution retrospective analysisOptimal timingCox proportional hazards modelExtracranial metastatic lesionsImproved overall survivalPrimary tumor locationMajority of patientsConcurrent systemic therapyMultivariate Cox analysisBody radiation therapyProportional hazards model